PLIANT THERAPEUTICS, INC.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On September 23, 2025, Bernard Coulie, our Chief Executive Officer, adopted a trading plan, or the Coulie 10b5-1 Sales Plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. Under the Coulie 10b5-1 Sales Plan, which goes into effect on January 19, 2026, an aggregate of 81,756 shares of the Company's common stock (the "Coulie Authorized Shares") may be sold. The Coulie 10b5-1 Sales Plan, which was entered into during an open trading window under the Company's insider trading policy, will be in effect until the earlier of (1)December 31, 2026 or (2) the date on which all Coulie Authorized Shares have been sold under the Coulie 10b5-1 Sales Plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.